Fastest Response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT
Lead
Hoffmann-La Roche
With
Zealand Pharma
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with BMI ≥ 27 kg/m²
T2D diagnosis as per World Health Organization (WHO) classification (or other locally applicable standards) with HbA1c ≥ 6.5% to ≤ 10% (48-86 mmol/mol), measured by the central laboratory at screening
Stable treatment with either diet and exercise alone, basal insulin, or selected oral glucose-lowering agents, for at least 90 days prior to and during screening
History of at least one self-reported unsuccessful dietary effort to lose body weight
You may not be if
History or presence of proliferative diabetic retinopathy, or diabetic macular edema
Current or previous treatment with petrelintide or any other amylin analog
Clareo Health | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
